➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKesson
Moodys
Harvard Business School
McKinsey

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00067340 ↗ Caries Transmission Prevention in Alaska Native Infants Terminated National Institute of Dental and Craniofacial Research (NIDCR) Phase 3 2003-04-01 The purpose of this study is to conduct a community based, randomized control trial to determine if the use of chlorhexidine mouth rinse and xylitol-sweetened chewing gum will reduce the vertical transmission of caries between Alaska Native mothers to their infants.
NCT00067340 ↗ Caries Transmission Prevention in Alaska Native Infants Terminated University of Washington Phase 3 2003-04-01 The purpose of this study is to conduct a community based, randomized control trial to determine if the use of chlorhexidine mouth rinse and xylitol-sweetened chewing gum will reduce the vertical transmission of caries between Alaska Native mothers to their infants.
NCT00111956 ↗ Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 2004-04-01 Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00985244 ↗ Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease Completed Amphia Hospital N/A 2010-05-01 To assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in the year of treatment.
NCT00985244 ↗ Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease Completed Erasmus Medical Center N/A 2010-05-01 To assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in the year of treatment.
NCT00985244 ↗ Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease Completed Stichting Solong N/A 2010-05-01 To assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in the year of treatment.
NCT00985244 ↗ Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease Completed R.S. Djamin N/A 2010-05-01 To assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in the year of treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Condition Name

Condition Name for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Acne Vulgaris 2
Surgical Site Infection 2
Pelvic Organ Prolapse 1
Cervicitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Infection 4
Urinary Tract Infections 2
Fibrosis 2
Surgical Wound Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Trials by Country

Trials by Country for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Location Trials
United States 11
India 4
Netherlands 2
Egypt 2
Brazil 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Location Trials
Minnesota 2
Delaware 1
Georgia 1
California 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Phase 4 15
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Not yet recruiting 11
Completed 10
Recruiting 8
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Sponsor Name

Sponsor Name for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
University of Campinas, Brazil 1
University of Oslo 1
Ain Shams Maternity Hospital 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
Other 45
Industry 7
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Merck
Johnson and Johnson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.